Valuation : Genexine, Inc.

Market Cap 24TCr 18Cr 16Cr 15Cr 13Cr 25Cr 1.73TCr 25Cr 175.55Cr 68Cr 880.61Cr 68Cr 67Cr 2.78TCr P/E 2022
-8.34x
P/E 2023 -5.99x
Enterprise Value 25TCr 18Cr 16Cr 15Cr 14Cr 25Cr 1.75TCr 26Cr 177.68Cr 68Cr 891.28Cr 69Cr 67Cr 2.82TCr EV / Sales 2022
33x
EV / Sales 2023 93.4x
Free-Float
86.57%
Yield 2022 *
-
Yield 2023 -
28/04 Genexine Inc Demonstrates First-In-Class Sox2 Degrader Gx-Bp1 in Preclinical Models CI
16/03 Egret Therapeutics, Inc and Genexine, Inc Sign Memorandum Of Understanding For Asset Transfer Of GX-P1 (EGT-101) CI
16/03 Egret Therapeutics Inc. signed a non-binding Memorandum of Understanding to acquire full right, title, and interest in lead asset EGT-101 (GX-P1) from Genexine, Inc.. CI
01/25/01 Genexine, Inc. announced that it has received KRW 19.4 billion in funding from Mirae Asset Securities Co., Ltd., Ds Investment & Securities Co.,Ltd., Synergy IB Investment Co., Ltd., Synergy-Premier Mezzanine Blind No. 1 New Technology Business Investment Fund, BNK Securities Co.,Ltd., Korea Investment & Securities Co., Ltd. CI
23/25/23 Genexine, Inc. announced that it expects to receive KRW 19.4 billion in funding from Mirae Asset Securities Co., Ltd., Ds Investment & Securities Co.,Ltd., Synergy IB Investment Co., Ltd., Synergy-Premier Mezzanine Blind No. 1 New Technology Business Investment Fund, BNK Securities Co.,Ltd., Korea Investment & Securities Co., Ltd. CI
07/25/07 Boehringer Ingelheim Ends Development of Steatohepatitis Drug, Returns Rights to Yuhan MT
01/24/01 Genexine, Inc. completed the acquisition of EPD Biotherapeutics Inc. CI
04/24/04 Genexine, Inc. Appoints Jaehyun Choi as Head of R&D CI
26/24/26 Genexine, Inc. signed a letter of intent to acquire EPD Biotherapeutics Inc. for KRW25.6 billion. CI
14/24/14 Genexine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
14/23/14 Genexine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
23/23/23 Genexine, Inc. and PT Kalbe Genexine Biologics Receives the First Market Approval for Novel Long-Acting Erythropoietin, Efepoetin Alfa, from the Indonesian Food and Drug Authority CI
31/23/31 Salesforce Earnings, Inflation Outlook Bolster Exchange-Traded Funds, Equity Futures Premarket Thursday MT
1 day-1.90%
1 week-13.04%
Current month+7.18%
1 month+4.23%
3 months-5.18%
6 months-42.38%
Current year-39.49%
1 week 2,815
Extreme 2815
3,155
1 month 2,470
Extreme 2470
3,880
Current year 2,140
Extreme 2140
7,490
1 year 2,140
Extreme 2140
7,490
3 years 2,140
Extreme 2140
11,870
5 years 2,140
Extreme 2140
59,230.77
10 years 2,140
Extreme 2140
1,46,384.62
Manager TitleAgeSince
Chief Executive Officer 51 26/03/2025
Chief Executive Officer 61 27/01/2023
Corporate Officer/Principal 49 01/01/2022
Director TitleAgeSince
Chairman 68 -
Director/Board Member 74 29/03/2022
Director/Board Member 61 27/01/2023
Date Insider Type Main position Quantity % Market Cap. Importance
22/10/24 Others 1,56,632 0.3773%
22/10/24 Others

Chief Executive Officer

16,91,165 4.0741%
22/10/24 Others 5,63,723 1.3580%
Change 5-day change 1-year change 3-year change Capi.($)
-1.90%-13.04%-49.01%-71.13% 9.77Cr
-2.11%-3.44%+41.04%+98.48% 6.82TCr
-0.23%-6.42%+30.19%+76.15% 6.22TCr
+1.70%+2.38%-11.31%+387.89% 2.78TCr
-1.05%-7.30%+25.00%+12.31% 2.49TCr
+0.48%-6.40%-6.89%-17.66% 2.42TCr
+0.43%-3.37%+14.85%-19.29% 1.94TCr
-3.03%-5.19%+192.88%+340.13% 1.73TCr
-1.94%-6.36%-7.05%+516.16% 1.45TCr
-2.27%-4.44%+44.33%+156.43% 1.42TCr
Average -0.93%-4.28%+27.40%+147.95% 2.73TCr
Weighted average by Cap. -0.81%-3.80%+32.86%+136.77%

Financials

2022 2023
Net sales 1.61TCr 1.2Cr 1.04Cr 98.22L 89.03L 1.67Cr 115.02Cr 1.68Cr 12Cr 4.49Cr 59Cr 4.52Cr 4.42Cr 184.92Cr 442.66Cr 33.02L 28.45L 26.94L 24.42L 45.81L 32Cr 46.04L 3.2Cr 1.23Cr 16Cr 1.24Cr 1.21Cr 51Cr
Net income -5.6TCr -4.18Cr -3.6Cr -3.41Cr -3.09Cr -5.79Cr -398.93Cr -5.82Cr -40Cr -16Cr -202.96Cr -16Cr -15Cr -641.33Cr -6.69TCr -4.99Cr -4.3Cr -4.07Cr -3.69Cr -6.92Cr -476.62Cr -6.96Cr -48Cr -19Cr -242.48Cr -19Cr -18Cr -766.21Cr
Net Debt 6.21TCr 4.64Cr 3.99Cr 3.78Cr 3.43Cr 6.43Cr 442.89Cr 6.46Cr 45Cr 17Cr 225.32Cr 17Cr 17Cr 711.99Cr 294.5Cr 21.97L 18.93L 17.92L 16.25L 30.48L 21Cr 30.63L 2.13Cr 81.86L 11Cr 82.51L 80.7L 34Cr
Logo Genexine, Inc.
Genexine Inc is a Korea-based company mainly engaged in the research and development of bio pharmaceuticals. The Company operates its business through two segments. The New Drug Development segment engages in human growth hormone, neutropenia treatment, anemia treatment, anticancer immunotherapy, hyFc platform, and other technology transfers. In addition, this segment sells the technical property rights of follicle-stimulating hormone. It also engages in cell line construction and sample production, project development, animal testing, human growth hormone development, and government agency research. The Medical Consumables segment produces and sells medical consumables such as medicine bags.
Employees
86
Date Price Change Volume
11/26/11 2,835.00 -1.90% 1,01,184
10/26/10 ₩2,890.00 -2.36% 1,63,964
09/26/09 ₩2,960.00 0.00% 1,19,853
08/26/08 ₩2,960.00 -3.11% 3,53,349
07/26/07 ₩3,055.00 +1.16% 3,01,263
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. A095700 Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!